January 1, 2015Open Access

First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype

Key Points

Key points are not available for this paper at this time.

Abstract

The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. pylori eradication compared to other first-generation PPIs.

First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype

Key Points

Abstract

Cite This Study